Profile:
Tau Therapeutics is a development stage biotechnology company built on the revolutionary discovery of how to stop tumor cells from growing. U.Va. pathology professor and founder Lloyd Gray discovered how to inhibit cell growth by blocking a type of calcium channel, termed the T-type channel. This novel target has significant implications for the treatment of cancer. Tau's innovative approach will lead to "treating cancer in an entirely different way," says CEO Andrew Krouse. "Tau is focused on maintenance therapy—which we believe is the future of cancer treatment."
Founder Timothy Macdonald, U.Va. professor of chemistry, notes that the obvious preferred strategy would be to eradicate cancer. However, years of research in anti-cancer drug development have come up short of a cure. "We're forging a new path," he says. "Let’s just stop the tumor cells from dividing and provide a meaningful increase in lifespan."
Tau's business approach is to reposition a drug as an anti-cancer therapy that should have much lower side affects than conventional cancer treatments. "Our goal is to treat cancer like any other chronic disease with a once-a-day anti-cancer pill," says Krouse. "Tau’s goal is to help people with cancer to live longer, healthier lives."
What's New:
Tau Therapeutics named as one of the Top 15 "best and brightest biotechnology companies" in the Southeast; 03.02.07; Tech Journal South. READ MORE
Tau Therapeutics closes $500,000 angel funding; 02.08.07; Tech Journal South. READ MORE
< Back to T100 |
